• Home
  • Programs
  • News
  • Publications
  • Team
  • Contact
Talk To Us
All articles

Fit-for-purpose delivery decreases risk

Published
2 Nov 2026
Reading time
6 min
Series
The Science Behind RT-100
Program
RT-100

Alan Horsager, PhD

President and CEO

Share

Summary

Gene therapy's serious safety events have shared a shape: a large dose, delivered into the bloodstream, to reach a large tissue. RT-100 is the opposite case on all three counts. It is infused into the coronary arteries rather than given intravenously, the heart is a small target, and the dose is a fraction of what whole-body programs require. Nearly 900 patients have been enrolled in randomized trials of gene transfer through the coronary arteries, and none of those trials reported a safety signal attributable to the vector.

Anyone who has followed gene therapy for more than a few years has reason to be cautious about it. The field has had deaths. Some of them changed how clinical research is regulated in the United States, and the most recent ones arrived while the field was being described as having matured past that history.

So the question is fair, and it comes up in nearly every meeting: why should anyone believe this program is different?

The answer isn't that Renova is more careful than everyone else. It's that “gene therapy” names a category far too broad to carry a single risk profile, in the same way “surgery” does. What actually drives the risk is how much vector you give, where you put it, and how much tissue you are trying to reach. RT-100 sits at the low end of all three.

Why the dose is set by the target, not by the drug

A gene therapy has to reach enough cells to matter. How much vector that takes depends almost entirely on how much tissue is involved.

Consider the arithmetic of the two extremes. Skeletal muscle is the largest tissue in the body, somewhere near 40 percent of body weight. A therapy that has to reach it has no realistic option but to dose intravenously, by body weight, and to accept that the vector will circulate everywhere the blood goes, including the liver. The heart is about 300 grams, roughly half a percent of body weight, and it comes with its own plumbing. A catheter threaded into the coronary arteries delivers the vector to the tissue you want and very little else.

That difference compounds. A smaller target means a smaller dose. A local route means less of what you give ends up in organs you weren't aiming at. And because the immune response to a viral vector scales with how much of it the body sees, a smaller systemic exposure means a smaller response to manage.

This is not a subtle effect. The highest dose of RT-100 given in the completed Phase 2 trial was 10¹² viral particles in total, not per kilogram, infused into the coronary arteries during a routine catheterization1. Programs that have to reach the whole muscle compartment dose by body weight into the bloodstream, which puts them orders of magnitude higher in total viral load. The serious liver toxicity that has driven recent concern in the field is a documented consequence of high systemic exposure. It is a problem of dose and route, and it tells you very little about what happens at a thousandth of the exposure delivered somewhere else.

The vector class matters too, in both directions

RT-100 uses an adenoviral vector rather than AAV, which is the vector behind most approved gene therapies. That difference cuts both ways, and it's worth being straight about it.

Adenovirus does not persist as long in most tissues, which is the subject of a separate post in this series. What it does do is avoid the particular failure mode that has caused the field's recent trouble, because the adenoviral programs in cardiology were never designed to flood the body in the first place. Adenovirus also has an approved product behind it: a bladder cancer therapy approved by the FDA in 2022 delivers an adenoviral vector directly into the bladder, the same philosophy of putting the vector where the tissue is2.

AAV is not inherently safer, and it isn't immunologically invisible. Immune responses to the AAV shell and its cargo are well documented in patients3. What separates the programs that have run into trouble from the ones that haven't is not which virus they chose. It's how much they had to give and where it went.

What the cardiac record actually shows

Intracoronary gene transfer is not new territory, which is the part of this story that tends to surprise people. Four randomized, placebo-controlled trials have now delivered gene therapy through the coronary arteries, enrolling nearly 900 patients between them.

Figure 1

Intracoronary gene transfer in randomized trials, by dose

Total viral particles per patient, delivered into the coronary arteries · dot size = patients enrolled · doses are totals, not per kilogram of body weight

Randomized trials of intracoronary gene transfer, by total dose per patientAGENT-3 and AGENT-4 (2007), 532 enrolled, low and high dose; Ad5FGF-4, early trial (2003), 52 enrolled, 10¹⁰ vp; RT-100, Phase 2 (2016), 56 enrolled, up to 10¹² vp; CUPID 2 (2016), 250 enrolled, 10¹³ particles.10⁹10¹⁰10¹¹10¹²10¹³10¹⁴AGENT-3 and AGENT-4 (2007)532 enrolledlow and high doseAd5FGF-4, early trial (2003)52 enrolled10¹⁰ vpRT-100, Phase 2 (2016)56 enrolledup to 10¹² vpCUPID 2 (2016)250 enrolled10¹³ particlesTotal viral particles per patient, delivered into the coronary arteriesDoses shown are totals, not per kilogram of body weight.
  • RT-100, Phase 2 (2016)
  • Other intracoronary trials

Enrolled

Nearly 900 patients across the four trials, placebo arms included

Randomized trials of gene transfer delivered through the coronary arteries. Doses are totals per patient rather than per kilogram. None of these trials reported a safety signal attributable to the vector; CUPID 2 and the AGENT trials did not meet their efficacy endpoints.

Sources: Grines CL et al., J Am Coll Cardiol 2003;42(8):1339–1347. Henry TD et al., J Am Coll Cardiol 2007;50(11):1038–1046. Hammond HK et al., JAMA Cardiol 2016;1(2):163–171. Greenberg B et al., Lancet 2016;387(10024):1178–1186.

An early trial of an adenoviral vector carrying a growth factor gene treated 52 patients at 10¹⁰ viral particles and reported that it was well tolerated, with no permanent adverse sequelae4. The two larger trials that followed in the same program enrolled 532 patients5.

The CUPID 2 trial delivered an AAV1 vector carrying SERCA2a, a gene in the same calcium-handling pathway RT-100 acts on, to 250 patients at 10¹³ particles by intracoronary infusion. It is the largest gene transfer study yet conducted in heart failure. It did not improve outcomes, and the authors reported no safety signals6. That result is worth sitting with for a moment: a dose ten times higher than the highest RT-100 dose, delivered by the same route, into the same organ, without a safety problem. CUPID 2 is usually cited as a disappointment for cardiac gene therapy, and on efficacy it was. On tolerability of the delivery approach it was informative in the other direction.

In Renova's own Phase 2 trial, 56 patients were randomized and 42 received RT-100 across five dose levels. Rates of serious adverse events were comparable between RT-100 and placebo. There was no liver injury, no myocarditis, and no increase in arrhythmias, which the trial was unusually well placed to detect because every participant had an implanted defibrillator providing continuous rhythm monitoring1.

What this doesn't settle

A safety record is not a guarantee, and there are limits to what the data above can support.

The RT-100 trial enrolled 42 treated patients. That is enough to detect a common problem and not enough to rule out a rare one. Only a larger trial can do that, and demonstrating safety at scale is part of what the next study is for.

The published cardiac experience also sits at doses up to 10¹³ particles. Any future trial that tests a higher dose is asking a question the existing record doesn't answer, and it should carry the oversight that goes with a first exposure at a new level, including independent monitoring with pre-specified stopping rules.

Finally, the trials described here measured antibody responses and clinical events. None of them characterized the T-cell response to the vector in treated patients. That gap matters for how long treated cells survive, and it's one we would like to close.

Gene therapy is not one thing, and its safety record cannot be read as one number. For a vector delivered into the coronary arteries, at doses far below those used to reach the whole body, the relevant human experience runs to hundreds of patients across four randomized trials. That is the record RT-100 is building on.

RT-100 is an investigational therapy. It has not been approved by the FDA or any other regulatory agency and is available only within clinical trials.

References

  1. 1. Hammond HK, Penny WF, Traverse JH, Henry TD, Watkins MW, Yancy CW, et al. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial. JAMA Cardiol. 2016;1(2):163–171. DOI
  2. 2. U.S. Food and Drug Administration. Adstiladrin (nadofaragene firadenovec-vncg), the first gene therapy for patients with high-risk non-muscle invasive bladder cancer, approved December 2022. Link
  3. 3. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23–36. DOI
  4. 4. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003;42(8):1339–1347. DOI
  5. 5. Henry TD, Grines CL, Watkins MW, Dib N, Barbeau G, Moreadith R, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007;50(11):1038–1046. DOI
  6. 6. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016;387(10024):1178–1186. DOI

Related news

All news and articles
  • Company News2 Nov 2026

    Renova assembles the team for RT-100's next trial

    Read the News
  • Science Series2 Nov 2026

    Durability depends on tissue type

    Read the News
Renova Therapeuticsinfo@renovagtx.com
Pasadena, California
  • Home
  • Programs
  • News
  • Publications
  • Team
  • Contact
  • LinkedIn
  • X
Sources
  1. 01

    American Heart Association. 2026 Heart Disease and Stroke Statistics Update. Link

  2. 02

    Gorodeski EZ et al. HF STATS 2026: An Updated Report on Heart Failure Epidemiology and Outcomes from the Heart Failure Society of America. J Card Fail. 2026. DOI

  3. 03

    Hammond HK et al. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial. JAMA Cardiol. 2016;1(2):163–171. DOI

  4. 04

    Penny WF, Hammond HK. Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction. Hum Gene Ther. 2017;28(5):378–384. DOI

© 2026 Renova Therapeutics, Inc.

  • Privacy Policy
  • Terms of Use